Skip to main content

Table 2 Risk of development of NODAT (unadjusted and adjusted) in Malaysian renal transplant recipients according to clinical characteristics presented as hazard ratio (HR) with 95% confidence of interval (CI)

From: Clinical and genetic risk factors for new-onset diabetes mellitus after transplantation (NODAT) in major transplant centres in Malaysia

Clinical characteristics Unadjusted
HR (95% CI), p
Adjusteda
HR (95% CI), p
Gender b
 - Females 0.99 (0.65, 1.52), 0.98 0.70 (0.34, 1.43), 0.33
Age at transplant 1.04 (1.02, 1.06), < 0.0001 1.01 (0.97, 1.06), 0.56
Ethnicitiesc
 - Chinese 2.27 (1.13, 4.54), 0.02 1.46 (0.43, 4.96), 0.55
 - Indian 2.19 (0.91, 5.27), 0.08 1.88 (0.47, 7.55), 0.37
Primary kidney diseased
 - Hypertension 1.89 (1.05, 3.39), 0.03 1.10 (0.38, 3.21), 0.86
 - Others 0.84 (0.58, 1.53), 0.82 0.77 (0.17, 3.55), 0.74
Type of donore
 - Living related 1.07 (0.69, 1.65), 0.51 0.60 (0.17, 2.07), 0.59
 - Living non-related 0.65 (0.29, 1.45), 0.29 0.58 (0.18, 1.9), 0.38
Place of transplantf
 - Overseas 1.42 (0.93, 2.17), 0.10 1.04 (0.42. 2.56), 0.93
Types of calcineurin inhibitorsg
 - Tacrolimus 0.95 (0.61, 1.47), 0.81 0.95 (0.60, 1.51), 0.84
 - Both 1.26 (0.54, 2.96), 0.59 0.89 (0.37, 2.12), 0.79
Duration of dialysis (month) 0.99 (0.90, 0.99), 0.04 0.99 (0.98, 1.01), 0.27
BMI post-transplant 1.01 (0.97, 1.06), 0.44 0.93 (0.81, 1.06), 0.29
Levels of creatinine post-transplant 1.00 (0.99, 1.00), 0.58 1.00 (0.99, 1.02), 0.62
Average daily dose of cyclosporine 1.01 (1.00, 1.01), < 0.0001 1.01 (1.00, 1.01), 0.002
Average daily dose of tacrolimus 1.15 (1.03, 1.27), 0.009 1.10 (0.98, 1.23), 0.11
Average daily dose of prednisolone 1.11 (1.06, 1.16), < 0.0001 1.07 0.96, 1.20), 0.23
  1. aAdjusted for age at transplant, ethnicities, primary kidney disease, duration of dialysis pre-transplant and doses of immunosuppressants
  2. b reference: Males c reference: Malay ethnicities
  3. d reference: Glomerulonephritis e reference: Cadaveric donor
  4. f reference: Transplanted in Malaysia g reference: cyclosporine as immunosuppressant